Lamassu Biotech Reports Initial SA53 Safety Data at ESMO
The company reported no dose-limiting toxicities and no Grade 2 or higher treatment-emergent adverse events through four dose levels in its first-in-human Phase 1/2a study.
The company reported no dose-limiting toxicities and no Grade 2 or higher treatment-emergent adverse events through four dose levels in its first-in-human Phase 1/2a study.